Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.
about
Structural insights on the role of antibodies in HIV-1 vaccine and therapyMutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.Early antibody therapy can induce long-lasting immunity to SHIVAntibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocksMultimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunizationVaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaquesEmergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoproteinRepertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencingA single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesMacaque-tropic human immunodeficiency virus type 1: breaking out of the host restriction factorsOf Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection.Development of SHIVs with circulating, transmitted HIV-1 variants.A single gp120 residue can affect HIV-1 tropism in macaques.A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.
P2860
Q26829461-1922C097-78B9-494D-8B88-70ECD075B45EQ30368471-A3D28A2A-0F18-4AA8-9026-D30203F4A2F1Q33597744-366D20B7-74E8-4C01-B858-E2DD52203419Q33762877-C0D7E577-84C1-4D16-87F6-25FCC9F3CCCBQ34049077-8D6E457E-F8FC-4168-AC32-A906D93C9FB7Q34230556-0DB557C2-C1DD-460B-8C5E-6502F54EF5E0Q35115599-5E5255CA-1563-4EDE-A705-C46EF2C55E11Q35129224-60A12C45-D01F-443C-99DA-D44E3453451CQ35487441-88BB4691-4BEA-461C-BEA7-CAB55BB9CAAAQ35914306-71FCD96A-3F42-48C7-A296-1F72859D8725Q36438523-07B3E9C6-D16E-4853-B638-90A116C3B6B8Q36608554-FBAE6CE6-2DE1-49CE-8DC7-64EC843984FFQ37002517-394B03FA-06FA-4216-A4FC-FE94BFD8E2B7Q37021717-E7389CB5-B9A1-481E-A65E-5415FBC08473Q37036833-B3C98AC3-9802-4960-BB4C-924EF83703D0Q37151457-B2168C4D-1BEE-4DA5-8276-43CCB0669646Q37450695-903E1FE0-EE7D-47BD-B8D6-598FA55EE261Q37621530-E448B543-7D05-4F8C-9FEA-7F0045B3D151Q38121073-FBF32F70-5F74-45E8-B1C4-30CD6E8F4E9EQ38643834-F8DB67E8-7ABD-416C-876F-2061E93FB62DQ40055103-0A5B0463-3FFC-40C6-94C5-535F5940FCD6Q40681333-045EF44D-BEEF-4479-AF41-A099E32389EBQ41144765-A6AAB56B-672C-43D1-AF73-709652572B6DQ41930708-6C037084-72E7-4931-9CBC-36F00FF042FFQ52584556-FE75524C-4083-4420-BC38-F92FAD6374B8
P2860
Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pathogenicity and mucosal tran ...... ns for use in vaccine studies.
@ast
Pathogenicity and mucosal tran ...... ns for use in vaccine studies.
@en
type
label
Pathogenicity and mucosal tran ...... ns for use in vaccine studies.
@ast
Pathogenicity and mucosal tran ...... ns for use in vaccine studies.
@en
prefLabel
Pathogenicity and mucosal tran ...... ns for use in vaccine studies.
@ast
Pathogenicity and mucosal tran ...... ns for use in vaccine studies.
@en
P2093
P2860
P50
P356
P1433
P1476
Pathogenicity and mucosal tran ...... ns for use in vaccine studies.
@en
P2093
Alicia Buckler-White
Celia C LaBranche
Malcolm A Martin
Masashi Shingai
Olivia Donau
Rajeev Gautam
Reza Sadjadpour
Stephen D Schmidt
Wendy R Lee
Yoshiaki Nishimura
P2860
P304
P356
10.1128/JVI.00644-12
P407
P577
2012-05-30T00:00:00Z